Characterization of Human Tissue-Type Plasminogen Activator with Monoclonal Antibodies: Mapping of Epitopes and Binding Sites for Fibrin and Lysine

Summary

The study defines interactions between human tissue-type plasminogen activator (t-PA) and 21 mouse monoclonal antibodies (mAb). Characterization includes epitope distribution, reactivity of different forms of t-PA with antibodies, and modification of t-PA function by antibody binding.

Eighteen antibodies are directed against t-PA A-chain. These antibodies recognize four distinct epitopes (A, B, C, D) and one partially overlapping epitope (D’). The remaining three antibodies are directed against two different epitopes (E, F) on catalytically active t-PA B-chain. A-chain reactive antibodies do not bind to the reduced form of t-PA, while B-chain reactive antibodies bind to reduced and deglycosylated t-PA forms. The latter antibodies associate more tightly with sc t-PA than with tc t-PA and have a higher affinity for t-PA-PAI 1 complex as compared to free t-PA.

The analysis of functional effects of antibodies reveals that antibodies directed against all above defined epitopes inhibit interactions between t-PA and fibrin: a) binding of t-PA to fibrin, b) fibrinolytic activity of t-PA, and c) fibrin activation of sc t-PA amidolytic activity. The observations support the assumption that several sites of t-PA are involved in fibrin binding and that fibrin-bound t-PA is closely surrounded by the fibrin mesh. Many antibodies quench also binding of t-PA to lysine-Sepharose. Experiments with free, non-fixed lysine confirm strong competition between lysine and mAb 16 and 18, directed against epitope A, and mAb 29, binding to epitope F. Weak inhibition is exerted on association of mAb 2, 21, and 25 to epitope D. Amidolytic activity is suppressed only by B-chain specific antibody 22.

• References

• 1 Dano K, Andreason PA, Grondahl-Hansen J, Kristensen P, Neilson LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139-266
• 2 Will H. Plasminogen activators: molecular properties, biological cell function and clinical application. Progr Clin Biochem Med 1988; 7: 103-146
• 3 Topol EJ. Recombinant tissue plasminogen activator: implications in therapy. Sem Hematol 1989; 26: 25-31
• 4 Van Zonneveld AJ, Veerman H, Pannekoek H. On the interaction of the finger and kringle-2 domain of tissue-type plasminogen activator with fibrin. J Biol Chem 1986; 261: 14214-14218
• 5 Verheijen JH, Caspers MP, Chang GT, De Munk GA, Pouwles P, Enger-Valk BE. Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin. EMBO J 1986; 5: 3525-3530
• 6 Petersen LC, Johannessen M, Forster D, Kumar A, Mulvihill E. The effect of polymerized fibrin on the catalytic activities of one-chain tissue type plasminogen activator as revealed by an analogue resistant to plasmin cleavage. Biochim Biophys Acta 1988; 952: 245-254
• 7 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. J Biol Chem 1982; 257: 2912-2919
• 8 Ichinose A, Takio K, Fujikawa K. Localization of the binding site of tissue-type plasminogen activator to fibrin. J Clin Invest 1986; 78: 163-169
• 9 Madison EL, Goldsmith EJ, Gerard RD, Gething MJ, Sambrook JF. Serpin-resistant mutants of human tissue-type plasminogen activator. Nature 1989; 339: 721-724
• 10 Holvoet P, Lijnen HR, Collen D. Characterization of functional domains in human tissue-type plasminogen activator with the use of monoclonal antibodies. Eur J Biochem 1986; 158: 173-177
• 11 Wojta J, Beckmann R, Turcu L, Wagner OF, Van Zonneveld A, Binder BR. Functional characterization of monoclonal antibodies directed against fibrin binding domains of tissue-type plasminogen activator. J Biol Chem 1989; 264: 7957-7961
• 12 Fischer BE, Zacharias U, Wernicke D, Will H. Purification of human tissue-type plasminogen activator (t-PA) from melanoma cell culture medium by different affinity chromatographic methods. Acta Biotech-nol 1990; 10: 355-360
• 13 Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497
• 14 Stänker LH, Vanderlaan M, Jurarez-Salinas H. Purification of mouse monoclonal antibodies by hydroxylapatite. J Immunol Meth 1985; 76: 157-162
• 15 Wood JN. Immunofluorescence and immunoperoxidase screening of hybridomas. Meth Mol Biol 1984; 1: 271-278
• 16 Nakane PA, Kawaoi A. Peroxidase labeled antibody. A new method of conjugation. J Histochem Cytochem 1974; 22: 1084-1091
• 17 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
• 18 Towbin H, Staehlin T, Gardon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4354
• 19 Jespersen J, Astrup T. A study of the fibrin plate assay of fibrinolytic agents. Optimal conditions, reproducibility and precision. Haemostasis 1983; 13: 301-310
• 20 Brosstad F, Godal MC, Kierulf P. Some characteristics of various fibrin monomer preparations made from dissolved fibrin clots. Haemostasis 1977; 6: 213-224
• 21 Davies DR, Sheriff S, Padlan EA. Antibody-antigen complexes. J Biol Chem 1988; 263: 10541-10544
• 22 Berzofsky JA. Monoclonal antibodies as probes of antigenic structure. In: Monoclonal and Anti-Idiotypic Antibodies: Probes for Receptor Structure and Function. Liss AR. (ed). 1984. pp 1-19
• 23 Lijnen HR, Nelles L, Van Hoef B, Demarsin E, Collen D. Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single chain urokinase-type plasminogen activator. J Biol Chem 1988; 263: 19083-19091
• 24 Van Zonneveld AJ, Veerman H, Brakenhoff JP, Aarden LA, Cajot JF, Pannekoek H. Mapping of epitopes on human tissue-type plasminogen activator with recombinant deletion mutant proteins. Thromb Haemostas 1987; 57: 82-86
• 25 Hart DA, Rehemtulla A. Plasminogen activators and their inhibitors: regulators of extracellular proteolysis and cell function. Comp Biochem Physiol 1988; 90B: 691-708
• 26 Gething MJ, Adler B, Boose JA, Gerard RD, Madison EL, Me Gookey D, Meidell RS, Roman LM, Sambrook J. Variants of human tissue-type plasminogen activator that lack specific structural domains of the heavy chain. EMBO J 1988; 7: 2731-2740
• 27 Stern A, Weidle UH. Kringle 1 domain of human tissue-type plasminogen activator is a functional module mediating fibrin-stimulated plasminogenolytic activity. Gene 1990; 87: 305-308